| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | 0.08 | 0.02 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.02 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.51 | 0.02 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | 0.079 | 0.02 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | niclosamide | CTRPv2 | pan-cancer | AAC | -0.092 | 0.02 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.02 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | 0.085 | 0.02 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.082 | 0.02 |